Harnessing Therapeutic Potentials of Statins Using Nanofibrous Carriers

Table 2

Summary of in vivo application of statins in various studies.

Application	Reference	Animal model	Lesion type	Product	Dose	Treatment duration	Authors’ stated main results
Bone regeneration	[35]	Sprague-Dawley rats	Rat calvarial defects	Chitosan with or without SIM-loaded NFMs	0.25 mg of simvastatin	8 weeks	There was no significant difference between the control and experimental groups
	[36]	Wistar albino rats	Rat calvarial defects	SIM-loaded electrospun spiral-wound PCL scaffolds	20 μg	6 months	The SIM NFs after 3–6 months significantly reconstructed the 8 mm calvarial defect with increase in the mineralization rate compared to free PCL scaffolds
	[37]	Mice (C57/bl/6j, 4 weeks old, male)	Bilateral dorsal skin	SRBFS	0.025 wt%	12 weeks	SRBFS promoted substantially higher bone formation than the free scaffolds (BFS) after 12 weeks of implantation on mice.
	[22]	Wistar rats	5–7 mm femoral defect	SIM and/or ezetimibe-loaded-PU-NFs	0.471 mg/oval fracture shape	4 weeks	SIM and/or ezetimibe-loaded PU-NFs showed significant bone curing and increased bone density
Endothelization and antithrombotic effects	[38]	Rabbit aneurysm model	Intracranial aneurysm in a rabbit carotid artery aneurysm	AtvCa in the inner of PLCL-NFs-covered stents	5, 10, 15, and 20 mg	One month	Aneurysms completely disappeared; PLCL-AtvCa10 showed the best results, including reendothelization and intimal hyperplasia
	[39]	Rabbit aneurysm model	Rabbit right CCA aneurysm	A heparin-Rosu-P(LLA-CL) NF-covered stent	10 mg/mL rosuvastatin	4 months	Among different formulations, Rosu 100 showed the best effectiveness in reducing in-stent stenosis and thrombosis
Neuroprotection	[44]	Sprague-Dawley male rats	Sciatic nerve crush injury	ALA-ATR composite NFs	-	One month	ALA/ATR showed better results than other formulations